Compare
Traws Pharma, Inc. vs Longeveron Inc. vs Lantern Pharma Inc. vs Decoy Therapeutics Inc.
| Latest fiscal year | Traws Pharma, Inc. TRAWRevenue covers only part of its income (partial revenue) | Longeveron Inc. LGVN | Lantern Pharma Inc. LTRN | Decoy Therapeutics Inc. DCOY |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $1.20M | n/a | n/a |
| Revenue growth (YoY) | n/a | -49.9% | n/a | n/a |
| Gross margin | n/a | 67.0% | n/a | n/a |
| Operating margin | n/a | n/m | n/a | n/a |
| Net margin | n/a | n/m | n/a | n/a |
| Net income | $9.17M | -$22.70M | -$17.12M | -$12.52M |
| EPS (Diluted) | $0.82 | -$1.29 | -$1.57 | -$129.10 |
| Operating cash flow | -$18.18M | -$18.64M | -$15.68M | -$4.83M |
| Free cash flow | -$20.77M | -$18.89M | -$15.68M | -$5.40M |
| Cash & equivalents | n/a | $4.66M | $4.42M | $10.71M |
| Total assets | $10.62M | $10.26M | $11.04M | $11.06M |
| Total liabilities | $11.25M | $4.59M | $4.50M | $5.17M |
| Shareholders' equity | -$629.0K | $5.67M | $6.53M | $5.89M |
| Return on year-end equity | n/a | -400.1% | -262.0% | -212.6% |
| Shares outstanding | 9.07M | n/a | 11.25M | n/a |
Revenue, most recent five fiscal years
| Fiscal year | Traws Pharma, Inc. | Longeveron Inc. | Lantern Pharma Inc. | Decoy Therapeutics Inc. |
|---|---|---|---|---|
| Latest | n/a | $1.20M Ended 2025-12-31 | n/a | $0 Ended 2022-12-31 |
| 1 year earlier | n/a | $2.39M Ended 2024-12-31 | n/a | $1.84M Ended 2021-12-31 |
| 2 years earlier | n/a | $709.0K Ended 2023-12-31 | n/a | $5.23M Ended 2020-12-31 |
| 3 years earlier | n/a | $1.22M Ended 2022-12-31 | n/a | $3.47M Ended 2019-12-31 |
| 4 years earlier | n/a | $1.31M Ended 2021-12-31 | n/a | $1.95M Ended 2018-12-31 |